Pay-for-delay cannot be per se violation, says Third Circuit
The US Court of Appeals for the Third Circuit has ruled that pharmacies’ antitrust claims against Pfizer and Ranbaxy were correctly dismissed, due to the plaintiffs’ insistence that an allegedly anticompetitive reverse payment inherently violated California antitrust law.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10